Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: Cross sectional study

BMJ (Online)

Volumn 343, Issue 7827, 2011, Pages

  Neuman, Jennifer ^a   Korenstein, Deborah ^a   Ross, Joseph S ^b   Keyhani, Salomeh ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; HYPERLIPIDEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; SCREENING TEST; UNITED STATES;

CANADA; COMMITTEE MEMBERSHIP; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DISCLOSURE; DRUG INDUSTRY; FINANCIAL SUPPORT; HUMANS; HYPERLIPIDEMIAS; MASS SCREENING; POLICY; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84859003754     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5621     Document Type: Article

References (27)

1. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 2011;305:1008-17.
2. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70. (Pubitemid 36649048)
3. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344.
4. Lundh A, Barbateskovic M, Hrobjartsson A, Gotzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue-cohort study. PLoS Med 2010;7:e1000354.
5. Drazen JM, de Leeuw PW, Laine C, Mulrow C, Deangelis CD, Frizelle FA, et al. Towards more uniform conflict disclosures: the updated ICMJE conflict of interest reporting form. BMJ 2010;340:c3239.
6. Chimonas S, Frosch Z, Rothman DJ. From disclosure to transparency: the use of company payment data. Arch Intern Med 2011;171:81-6.
7. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-12. (Pubitemid 351549971)
8. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ 2008;336:1402-3. (Pubitemid 351946976)
9. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6. (Pubitemid 28042274)
10. Holloway RG, Mooney CJ, Getchius TS, Edlund WS, Miyasaki JO. Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines. Neurology 2008;71:57-63.
11. Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, Gutterman D, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med 2010;152:738-41.
12. Steinbrook R. Guidance for guidelines. N Engl J Med 2007;356:331-3. (Pubitemid 46148775)
13. Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J. Conflicts of interest and disclosure in the American Psychiatric Association's clinical practice guidelines. Psychother Psychosom 2009;78:228-32.
14. Okike K, Kocher MS, Wei EX, Mehlman CT, Bhandari M. Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med 2009;361:1466-74.
15. World Health Organization. WHO handbook for guideline development. WHO, 2008.
16. National Institute for Health and Clinical Excellence. Code of practice for declaring and dealing with conflicts of interest: NICE, 2008.
17. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research EaP. Conflict of interest in medical research, education, and practice. National Academies Press, 2009.
18. Agency for Healthcare Research and Quality. Household and pharmacy components of the medical expenditure panel survey. AHRQ, 2007.
19. National Institute for Health and Clinical Excellence. Are you taking part in a NICE advisory body meeting? Do you have a conflict of interest you need to declare? 2007. www.nice.org.uk/media/134/39/ CodePractice2AdvisoryBodyQuickGuide.pdf.
20. World Health Organization. Declaration of interests for WHO experts. 2010. http://keionline.org/node/1062.
21. Mendelson TB, Meltzer M, Campbell EG, Caplan AL, Kirkpatrick JN. Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med 2011;171:577-84.
22. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301:831-41.
23. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-7. (Pubitemid 34252013)
24. US Preventive Services Task Force. U.S. Preventive Services Task Force procedure manual . USPSTF Program Office, 2011.
25. Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000;355:103-6. (Pubitemid 30068554)
26. Keyhani S, Kim A, Mann M, Korenstein D. A new independent authority is needed to issue national health care guidelines. Health Aff (Millwood) 2011;30:256-65.
27. Institute of Medicine. The global use of medications outlook through 2015. IMS, 2011.